Valve disease

Should patients with asymptomatic mild or moderate aortic stenosis undergoing coronary artery bypass surgery also have valve replacement for their aortic stenosis?

Shahbudin H Rahimtoola
Division of Cardiology, Department of Medicine, University of Southern California and LAC+USC Medical Center, Los Angeles, California, USA

The older you get, the closer you are to death
—an old Asian saying

In 1994-96, three studies described patients who had previously undergone coronary artery bypass graft surgery (CABG) and then had subsequent aortic valve replacement (AVR) (the aortic stenosis was “mild to moderate” at time of initial CABG); these patients were subsequently associated with a “high” operative mortality of 14–19%.

From these studies arose the rationale that patients who have mild to moderate aortic stenosis at the time of CABG will develop severe aortic stenosis within 10 years; such patients should therefore have combined CABG+AVR at time of initial bypass surgery.

There were several problems with this rationale, which have been previously described in detail and are summarised below.

- Two subsequent studies showed that the operative mortality for later AVR, if necessary, was not significantly different from those undergoing CABG+AVR (0% and 7.7%).
- Most importantly, these studies provided no information on the numbers of patients during the same time period who had mild to moderate aortic stenosis but did not require AVR during subsequent follow-up.
- There was little or no documentation to show that the aortic stenosis was mild to moderate at the time of the initial CABG.
- Moreover, some patients already had severe aortic stenosis at the time of initial CABG which was misdiagnosed.
- At time of subsequent AVR, the documentation showing that aortic stenosis was severe was sketchy. Many patients had angina as their symptom and 46–75% of these patients also needed repeat CABG at the time of late AVR.
- There was very little or no documentation of the patients’ clinical condition at time of initial CABG and at the time of late AVR.

The rate of progression of aortic stenosis, the manner of progression and whether it was linear or not, and factors determining more rapid progression were not fully known, especially in patients who had undergone CABG.

### Severity of aortic stenosis

Aortic stenosis is considered to be mild when the calculated aortic valve area (AVA) is > 1.5 cm² (Table 1). An AVA ≤ 1.0 cm² or an AVA index ≤ 0.6 cm²/m² signify severe aortic stenosis. Reliance on gradients alone poses problems which have been previously described in detail.

The gradient across an aortic valve is related to flow across the valve in systole and is a “per beat”, and not a “per minute”, function. Thus, aortic valve gradient (AVG) is dependent on forward stroke volume from the left ventricle and systolic ejection time, both of which are a function of heart rate, and of left ventricular preload, afterload and myocardial contractility. AVG is also dependent on the distal obstruction (systemic vascular resistance), and thus, on the pressure in the ascending aorta. Therefore, AVGs can change from one minute to the next.

Measurement of gradients by Doppler ultrasound is clinically useful. However, their limitations must be kept in mind. Feigenbaum stated: “None of the echocardiographic techniques measures intravascular pressures directly.” The modified Bernoulli equation used to estimate gradients from Doppler velocities makes many assumptions, ignores several factors, and has been shown to be inaccurate in several subgroups.

Peak AVG by Doppler poses particular problems and it is better to calculate mean AVG. In 636 patients studied by cardiac catheterisation over a 10 year period, no AVG (peak or mean) was found that was both sensitive and specific for severe aortic stenosis. A mean gradient of ≥ 50 mm Hg or a peak gradient of ≥ 60 mm Hg were “specific” with a 90% or more positive predictive value. However, it was not possible to find a lower limit with 90% negative predictive value. The authors emphasised the importance of measuring AVG in all patients with suspicion of severe aortic stenosis with a cardiac catheterisation mean AVG ≤ 50 mm Hg (present in 50% of patients in their study) and a peak of < 60 mm Hg (present in 47% of patients in their study).

Patients with low mean AVG and reduced left ventricular ejection fraction (< 0.35) may have severe aortic stenosis and frequently have

---

**Table 1** Criteria for severity of aortic stenosis

<table>
<thead>
<tr>
<th>Aortic stenosis</th>
<th>AVA (cm²)</th>
<th>AVA² (cm²)</th>
<th>AVA³ (cm²)</th>
<th>AVA index (cm²/m²)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mild</td>
<td>&gt; 1.5</td>
<td>&gt; 1.5</td>
<td>&gt; 1.5</td>
<td>&gt; 0.9</td>
</tr>
<tr>
<td>Moderate</td>
<td>0.95–1.4</td>
<td>0.8–1.5</td>
<td>1.0–1.5</td>
<td>&gt; 0.6–0.9</td>
</tr>
<tr>
<td>Severe</td>
<td>&lt; 0.9</td>
<td>&lt; 0.8</td>
<td>&lt; 1.0</td>
<td>≤ 0.6</td>
</tr>
</tbody>
</table>

Superscripts denote reference source.

AVA, aortic valve area.
Results of CABG alone

- An operative (30 day) mortality of ≤ 3% in those aged < 80 years and of ≥ 8.1% in those aged ≥ 80 years (table 2).

- Many patients who undergo this operation will die from coronary artery disease, graft disease, graft occlusion, left ventricular dysfunction, and other comorbid conditions; approximately 30% at 10 years (table 3).

- A certain percentage will need repeat revascularisation for graft disease, graft occlusion, and progression of coronary artery disease—approximately 16% at 10 years.

Results of CABG+AVR initially

- An average operative mortality of 7.9% in those aged < 80 years and of 10.6% in those ≥ 80 years (table 2).

- Many patients will die from coronary artery disease, graft disease, graft occlusion, left ventricular dysfunction, and other comorbid conditions, and the survivors will be subject to prosthesis related deaths—approximately 60% at 10 years (table 3).

- A certain percentage will need repeat revascularisation for graft disease, graft occlusion, and progression of coronary artery disease—approximately 16% at 10 years.

- A significant percentage will have prosthesis related complications, including reoperation for prosthetic valve malfunction—up to approximately 2–6% per year.

Mild aortic stenosis

Of two studies on the natural history of mild aortic stenosis (AVA > 1.5 cm²) documented by cardiac catheterisation, one showed that by 10 years 8% of patients had developed severe aortic stenosis, and in the other the event rate (which includes AVR plus mortality before and after AVR) was 15%. Thus, it is likely that, at most, ≤ 12% of survivors who initially did not have AVR will develop severe aortic stenosis; even if one assumes that the operative mortality of late AVR in these patients may be up to 15% (probably too high an estimate of mortality rate with modern surgical technique), the total

Resolution of the problem

This clinical situation is more common in older patients (average age at time of initial CABG ≥ 60 years) and their mortality with or without surgery can be expected to be greater than in younger patients, especially if they have associated comorbid conditions. In the cited studies, late AVR was performed on average 8–9 years after the initial CABG.

Since there are no good prospective studies or trials addressing this clinical circumstance, one way to proceed is to: (1) determine the 10 year results of CABG+AVR; and (2) determine the 10 year results of isolated CABG and add to this the outcome of patients with mild to moderate aortic stenosis.
The natural history of moderate aortic stenosis is more difficult to estimate for a number of reasons. One study\(^2\) provided information only on event-free survival which was 100% at the end of three years and 35% at the end of 10 years. Since all the events occurred in the intervening years, the event-free survival at five years can be expected to be about 81%. The event-free survival includes AVR plus mortality before and after AVR; the need for late AVR is not given separately.\(^8\)

A further study classified moderate aortic stenosis as an AVA of \(0.8–1.5\) cm\(^2\).\(^9\) However, another study has shown that the incidence of death and AVR in patients with “moderate” aortic stenosis (AVA of \(0.7–1.2\) cm\(^2\)) is 10% per year\(^2\); many of these patients in fact had severe aortic stenosis,\(^9\)—that is, AVA \(\leq 1\) cm\(^2\) (table 1).

Other issues include the problem of assessing aortic stenosis progression, which has been extensively reviewed,\(^4\) and the conflicting data over whether aortic stenosis in older patients progresses more rapidly than in younger
patients. Thus, even if one assumes that 65% of the survivors who initially did not have AVR will develop severe aortic stenosis (an overestimate) and will need late AVR, and that the operative mortality of late AVR in these patients may be up to 15% (probably too high), the total number of deaths from late AVR will be quite small.

If initially, 100 patients had CABG+AVR, then at the end of 30 days, three years, and five years, the expected number of unnecessary AVRs would be 100, 100, and 85, and the number of excess deaths would be five, nine, and 13, respectively (table 5). It should be noted that the figures for reoperation, and mortality associated with reoperation, are included in the 10 year estimated outcome data in table 5 and fig 2.

At 10 years, to reduce six deaths from late AVR by a policy of AVR for moderate aortic stenosis at time of initial CABG in 100 patients (table 5), the projected cumulative incidence of unnecessary AVR would be 54 and that of excess deaths would be 24 when compared to a policy of initial isolated CABG and late AVR if necessary (fig 2).

In view of the uncertainty of the rate of progression of calcific aortic stenosis in older patients, at this time CABG for severe coronary artery disease plus AVR may be reasonable for moderate aortic stenosis with an AVA \( \leq 1.2 \text{ cm}^2 \) and an AVA index \( \leq 0.8 \text{ cm}^2/\text{m}^2 \) in patients \( \geq 60-65 \) years of age, provided the patients are not at high risk for thromboembolism, and thus can receive a biological valve (bioprosthesis).

In patients who initially had only CABG, at the time of subsequent AVR there is a risk of damage to internal mammary and vein grafts. Although this risk is small with appropriate care, and with skilled and experienced surgeons, it must be recognised this risk applies to reoperation in both subgroups (CABG and CABG+AVR).

**Figure 2.** Projected patient outcomes in those with severe coronary artery disease who are to undergo coronary bypass surgery and also have moderate aortic stenosis. AVR, aortic valve replacement; CBS, coronary bypass surgery.

**Table 6** Results after 10 years of a policy of initial CABG+AVR for mild and moderate aortic stenosis

<table>
<thead>
<tr>
<th></th>
<th>Severe CAD and mild AS: 100 patients</th>
<th>Severe CAD and moderate AS: 100 patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>To eliminate:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>– late AVR</td>
<td>9</td>
<td>46*</td>
</tr>
<tr>
<td>– deaths from late AVR</td>
<td>2</td>
<td>7</td>
</tr>
<tr>
<td>Results in</td>
<td></td>
<td></td>
</tr>
<tr>
<td>– unnecessary AVR</td>
<td>91</td>
<td>54</td>
</tr>
<tr>
<td>– excess deaths</td>
<td>29</td>
<td>24</td>
</tr>
</tbody>
</table>

*An overestimate—see text.

AS, aortic stenosis; CAD, coronary artery disease.
   • A review of severe aortic stenosis with low ejection fraction and low aortic valve gradient, emphasizing the importance of early diagnosis and management.


   • A large study documenting the need to obtain aortic valve areas to assess severity of aortic stenosis.


   • A study of over 67,000 patients describing the operative mortality of isolated aortic and mitral valve replacement and when combined with associated coronary bypass surgery.


Should patients with asymptomatic mild or moderate aortic stenosis undergoing coronary artery bypass surgery also have valve replacement for their aortic stenosis?

Shahbudin H Rahimtoola

Heart 2001 85: 337-341
doi: 10.1136/heart.85.3.337

Updated information and services can be found at:
http://heart.bmj.com/content/85/3/337

These include:

References
This article cites 21 articles, 4 of which you can access for free at:
http://heart.bmj.com/content/85/3/337#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Aortic valve disease (414)
- Drugs: cardiovascular system (8839)
- Interventional cardiology (2932)
- Epidemiology (3768)
- Hypertension (3004)
- Education in Heart (548)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/